Market Research Logo

Global Non-Small Cell Lung Cancer Drugs Market 2019-2023

Global Non-Small Cell Lung Cancer Drugs Market 2019-2023

About this market

The increasing prevalence and incidence of non-small cell lung cancer are one of the primary factors driving the global non-small cell lung cancer drugs market growth. The growing risk factors such as cigarette smoking, air pollution, secondary smoking, and occupational exposure is increasing the incidence of non-small cell lung cancer across the world. This will lead to an increase in the demand for non-small cell lung cancer drugs. Technavio’s analysts have predicted that the non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023.

Market Overview

Strong drug pipeline and recent drug approvals

One of the growth drivers of the global non-small cell lung cancer drugs market is the strong drug pipeline and recent drug approvals. The development of new drugs and their approvals are helpful for the treatment of non-small lung cancer, which is expected to drive the market during the forecast period.

The high cost of treatment

One of the challenges in the growth of global non-small cell lung cancer drugs market is the high cost of treatment. Non-small cell lung cancer can be treated by surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy which is very costly. Therefore, the high cost of treatment for non-small cell lung cancer will hamper the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the non-small cell lung cancer drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are using predictive biomarkers for the development of cost-effective therapies with improved clinical benefits. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Non-small cell lung cancer drugs Market 2019-2023

Technavio recognizes the following companies as the key players in the global non-small cell lung cancer drugs market: AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the use of predictive biomarkers for the development of cost-effective therapies.”

According to the report, one of the major drivers for this market is the strong drug pipeline and recent drug approvals.

Further, the report states that one of the major factors hindering the growth of this market is the side-effects of drugs.

Companies Mentioned

AstraZeneca

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
      • Table Segments of global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Biologics - Market size and forecast 2018-2023
      • Table Biologics - Market size and forecast 2018-2023 ($ millions)
      • Table Biologics - Year-over-year growth 2019-2023 (%)
    • Small molecule targeted therapy - Market size and forecast 2018-2023
      • Table Small molecule targeted therapy - Market size and forecast 2018-2023 ($ millions)
      • Table Small molecule targeted therapy - Year-over-year growth 2019-2023 (%)
    • Chemotherapy - Market size and forecast 2018-2023
      • Table Chemotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Chemotherapy - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Late-stage pipeline drugs
    • Market challenges
      • Table Patent expiry of drugs
      • Table Side-effects of non-small cell lung cancer drugs
      • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AstraZeneca
      • Table AstraZeneca - Vendor overview
      • Table AstraZeneca - Business segments
      • Table AstraZeneca - Organizational developments
      • Table AstraZeneca - Geographic focus
      • Table AstraZeneca - Key offerings
    • Bristol-Myers Squibb Company
      • Table Bristol-Myers Squibb Company - Vendor overview
      • Table Bristol-Myers Squibb Company - Business segments
      • Table Bristol-Myers Squibb Company - Organizational developments
      • Table Bristol-Myers Squibb Company - Geographic focus
      • Table Bristol-Myers Squibb Company - Key offerings
    • Eli Lilly and Company
      • Table Eli Lilly and Company - Vendor overview
      • Table Eli Lilly and Company - Business segments
      • Table Eli Lilly and Company - Organizational developments
      • Table Eli Lilly and Company - Geographic focus
      • Table Eli Lilly and Company - Segment focus
      • Table Eli Lilly and Company - Key offerings
    • F. Hoffmann-La Roche Ltd
      • Table F. Hoffmann-La Roche Ltd - Vendor overview
      • Table F. Hoffmann-La Roche Ltd - Business segments
      • Table F. Hoffmann-La Roche Ltd - Organizational developments
      • Table F. Hoffmann-La Roche Ltd - Geographic focus
      • Table F. Hoffmann-La Roche Ltd - Segment focus
      • Table F. Hoffmann-La Roche Ltd - Key offerings
    • Merck & Co., Inc.
      • Table Merck & Co., Inc. - Vendor overview
      • Table Merck & Co., Inc. - Business segments
      • Table Merck & Co., Inc. - Organizational developments
      • Table Merck & Co., Inc. - Geographic focus
      • Table Merck & Co., Inc. - Segment focus
      • Table Merck & Co., Inc. - Key offerings
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report